A new genetic marker, PPP2R1A mutations, has been linked to improved survival rates for patients treated with immunotherapy in ovarian and other cancers. Targeting this biomarker may further enhance treatment outcomes, suggesting a potential new therapeutic target.
Researchers have discovered that the down-regulation of YWHAB in ovarian cancer peritoneal metastasis cells promotes YAP signaling, enhancing chemotherapy resistance and maintaining stem-like characteristics. Targeting the YWHAB-YAP pathway may lead to innovative therapeutic strategies.
A new study found that moderate caloric restriction can preserve youthful ovarian follicles and reduce age-related tissue stiffness in rhesus macaques. This suggests that lifestyle-based strategies may help delay the decline in reproductive function associated with aging.
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
Weill Cornell Medicine researchers Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been awarded a $750,000 grant to study ovarian cancer, with a focus on harnessing immune cells and detecting the disease earlier. Their research aims to develop innovative strategies for eliminating metastatic tumors and preventing recurrence.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
Researchers discovered that ascites fluid produced by ovarian cancer suppresses cytotoxic lymphocytes, crippling immune cells' ability to kill cancer cells. Fats in ascites cripple NK cells, T cells, and innate T cells, which are attractive candidates for cellular immunotherapies.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
A new case report presents a highly unusual combination of two benign ovarian tumors: serous cystadenofibroma and collision lesions. Accurate preoperative diagnosis is critical for effective treatment planning, and this case emphasizes the need for personalized evaluation of each ovarian mass.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
A 'master regulator' gene, ZNFX1, has been identified that may help guide treatment in patients with therapy-resistant ovarian cancer. The expression of this biomarker correlates with improved survival outcomes.
This study reveals TRIM4's role in modulating hnRNPDL degradation, leading to reduced CDKN2C levels and decreased sensitivity to CDK4/6 inhibitors. TRIM4 expression is associated with resistance to the inhibitor TQB3616, highlighting its potential as a biomarker.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A novel subset of progenitor cells, called high-risk MSCs, reside in the stroma and promote DNA damage and tumor growth. These cells play a critical role in the initiation of ovarian cancer, particularly in older women or those with BRCA mutations.
Researchers found that Black women have nearly identical mutations to other populations but experience lower survival rates due to clinical factors. The study highlights the importance of studying different population groups to improve ovarian cancer healthcare and develop targeted treatments.
Researchers found that PRP treatment increased gene expression related to metabolism, cell survival, and communication between cells in cumulus cells. This suggests that PRP may help support egg development and fertility in women with poor ovarian response.
A new study from Rice University researchers introduces a theoretical framework that quantitatively predicts menopause timing by analyzing how ovarian follicles transition through different stages. The model explains why menopause occurs and sheds light on individual variability and cross-population differences, providing insights that...
Researchers discovered noncoding cryptic peptides as an alternative source of target antigens for ovarian cancer. The findings could improve treatment approaches by mobilizing the immune system to attack tumor cells.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Researchers found that women who had used the oral contraceptive pill had a lower risk of ovarian cancer, with a 39% reduced risk for those who had given birth to two or more children. The study also identified certain biomarkers and lifestyle factors associated with a lower risk of ovarian cancer, including lower body weight and short...
A mathematical modeling study suggests that removing fallopian tubes during other abdominal surgeries can lower ovarian cancer incidence by five percent. The approach could also reduce total healthcare costs in Germany, with estimated annual savings of over €10 million.
A real-world multicenter study found olaparib to be effective in maintaining remission with a 75.2% 1-year progression-free survival rate. The safety profile was consistent with known adverse events, primarily anemia and nausea.
The study found that Jinfeng pill treatment improved ovarian size, follicle development, and hormone levels in POR rat model. The combination therapy produced the most significant improvements, including increased VEGF expression and balanced hormones.
A new study published in Nature Medicine shows that AI-based models can accurately identify ovarian cancer in ultrasound images, achieving an accuracy rate of 86.3%. The models also reduce the need for expert referrals and misdiagnosis rates by 63% and 18%, respectively.
A new MRI-based imaging technique can rapidly assess ovarian cancer subtypes and their response to treatment, allowing for personalized treatment planning. The technique, called hyperpolarised carbon-13 imaging, distinguishes between two different subtypes of ovarian cancer and reveals their sensitivities to treatment.
Researchers at The Wistar Institute have discovered a new combination therapy approach that shrinks tumors and improves survival rates in metastatic ovarian cancer. By activating myeloid cells, the treatment overcomes immunosuppression around tumors and makes them more receptive to chemotherapy.
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
Researchers discovered that ovarian cancer produces IL-4 to create a protective environment, resisting immunotherapy. Blocking IL-4 with dupilumab-like drugs could enhance immunotherapy for ovarian cancer.
Researchers discovered a mechanism used by ovarian tumors to cripple immune cells by blocking the energy supply T cells depend on. The discovery points toward a promising new immunotherapy approach for treating ovarian cancer.
The researchers aim to establish targets for the vaccine by identifying proteins on the surface of early-stage ovarian cancer cells recognized by the immune system. If successful, clinical trials will begin to test the vaccine's effectiveness in preventing ovarian cancer, potentially offering a solution for women at high risk.
Researchers at MUSC Hollings Cancer Center have developed a new model for ovarian cancer that suggests serous uterine cancer may originate in the fallopian tubes, rather than the uterus. The model has already shown promising results in replicating high-grade serous ovarian and uterine cancers.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
A blood test combining AI, cell-free DNA, and protein biomarkers shows high accuracy in detecting ovarian cancer. The test distinguishes between benign growths and cancerous tumors, offering a potential affordable screening method for widespread use.
A novel in situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity is developed to treat ovarian cancer and metastases. The vaccine effectively induces potent anti-tumor immunity and inhibits primary and metastatic tumors, combined with PD-1 blocking.
Researchers have found that intraovarian PRP injection can improve the number and quality of blastocysts in POI mouse ovaries damaged by high doses of chemotherapy. The study also characterizes the protein content of PRP, suggesting its potential to enhance reproductive function.
Researchers identified over 3,000 harmful genetic changes in the RAD51C gene that increase ovarian cancer risk six-fold and breast cancer risk four-fold. These findings can help doctors and diagnostic laboratory scientists better assess cancer risk and provide more personalized care.
Researchers discovered a novel treatment that extends ovarian function in older mice by improving maintenance of the ovaries and preventing key age-related changes. The treatment also fixes hormone production and overall health, alleviating symptoms such as bone loss, cardiovascular disease, and cognitive decline.
Researchers found that symptom-triggered testing can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected. The UK's protocol for picking up early-stage disease is an effective way to diagnose even early-stage ovarian cancer, with complete surgical removal possible in more than three quarters of women.
Researchers analyzed data from 1741 women diagnosed with high-grade serous ovarian cancer and found that symptom-triggered testing can lead to diagnosis of low-disease spread cases. In most cases, complete surgical removal of the cancerous tissue was possible, challenging the assumption that symptoms always signal advanced disease.
A preclinical study led by Weill Cornell Medicine researchers found that the iron-chelating drug deferiprone can selectively target and kill ovarian cancer cells. By starving cancer cells of iron, deferiprone triggers a cellular stress response, prompting the immune system to attack them.
A study suggests that hydroxyurea alters the developmental process of ovarian follicles but not their quantity. Ovarian tissue samples from patients with SCD showed no significant difference in primordial follicle density between those who received hydroxyurea and those who did not.
A study of nearly half a million women found that endometriosis was associated with a higher risk of ovarian cancer. The risk was particularly elevated among women with ovarian endometriomas or deep infiltrating endometriosis, with a 19-fold increased risk for certain types of ovarian cancer.
A landmark study found women with severe endometriosis have a 10-fold increased risk of ovarian cancer, compared to those without the disease. The study analyzed over 78,000 women and revealed that those with severe endometriosis are also at higher risk for type I ovarian cancer.
Dr. Sanaz Memarzadeh and her team aim to improve treatment outcomes for patients with platinum-resistant ovarian cancer using adoptive T-cell therapy and natural killer cells. They hope to identify new targets and biomarkers for effective treatments.
Researchers at Wayne State University aim to develop improved treatments for ovarian cancer by targeting dual-specificity phosphatase 1, a protein involved in drug resistance. The four-year grant will support the study's efforts to improve survival and remission rates.
A new study from George Mason University found that trace amounts of non-essential elements, such as lead and mercury, in ovarian follicular fluid may impact IVF success rates. Higher concentrations of cobalt and copper were associated with a stronger ovarian response, while higher levels of lead were linked to reduced fertility.
Cleveland Clinic researchers have discovered a new location for the CD55 protein in ovarian cancer cells, which aids in their resistance to chemotherapy. Blocking this migration can disrupt cancer growth and lessen cell resistance. The findings may lead to improved treatment options for chemotherapy-resistant ovarian cancer.
Research links early menopause to higher risks of breast and ovarian cancer in women. Second-degree relatives also show increased risks for colon, prostate, and testicular cancers.
A large-scale study of 572 Asian families with BRCA1 and BRCA2 mutations found increased breast cancer risk over time, with highest incidence at age 55. The study provides a new framework for estimating cancer risks in Asian carriers, supporting tailored clinical management approaches.
A recent study investigated the causal relationships between sarcopenia-related traits, body mass index (BMI), and ovarian cancer risk. The research found that slower usual walking pace was associated with lower ovarian cancer risk, while high appendicular lean mass and high BMI were linked to increased risk. These findings highlight a...
A new machine learning assay combines cell-free DNA fragment patterns and protein biomarkers to differentiate patients with ovarian cancer from healthy controls. The approach has shown high accuracy in detecting the disease, outperforming current biomarkers.
Researchers developed a novel theranostic platform that combines PET imaging and therapeutic radionuclides to detect and treat ovarian cancer. The system uses the huAR9.6 antibody to target the MUC16 protein, showing promise for improved patient survival rates.
A new study suggests that targeting LTA4H improves the tumor immune microenvironment and increases sensitivity to cisplatin therapy in ovarian cancer. High expression of LTA4H indicates poor prognosis and is associated with decreased CD8+ cell infiltration.
A new study from Uppsala University found that women with germ cell tumors have a significantly lower five-year survival rate (85.2%) compared to men (98.2%). The researchers suggest that concentrating patients in fewer hospitals and using treatment strategies for testicular cancer could improve survival rates and reduce side effects.
A new study published in Menopause reveals that aggregate exposure to neighborhood poverty is associated with increased levels of antimullerian hormone, potentially causing greater ovarian follicle loss over time. This finding highlights the potential effect of early life adversity on reproductive health.
Researchers at Johns Hopkins Kimmel Cancer Center and University School of Medicine developed an algorithm, REAL-FAST, to identify high-risk precancerous lesions on the fallopian tubes. The test accurately detected cancer 95.8% of the time and correctly ruled out cancer 97.1% of the time.
A new study published in Oncotarget reveals a higher prevalence of germline BRCA1 and BRCA2 mutations in ovarian cancer patients from the Salento peninsula, with 28.6% having familial cases and 39.7% having sporadic cases. The study found that 29.8% of patients were carriers of BRCA1/2 mutation.